Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nigella sativa hydroalcoholic extract is a botanical preparation derived from the seeds of *Nigella sativa* (commonly known as black seed or black cumin). The extract contains a variety of bioactive phytochemicals, most notably thymoquinone, which exhibit anti-inflammatory, antioxidant, immunomodulatory, and neuroprotective properties. It has been clinically evaluated both as a standalone therapy and in combination with other botanical extracts (such as flaxseed) for the management of fatigue in patients with relapsing-remitting multiple sclerosis (RRMS), as well as for pediatric epilepsy and diabetic nephropathy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nigella sativa hydroalcoholic extract.